drugset / Trial / NCT06077903
GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is a single center, single arm phase I clinical trial. This study proposes to enroll 20 subjects, with a trial protocol including chemotherapy pretreatment, reinfusion of autologous tumor infiltrating lymphocyte injection, and interleukin-2 injection.
Timeline
- Start
- 2021-07-05
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Outcome
Outcome not reported
Stopped (Business): “The study was terminated from a business perspective.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT101 | Cell therapy | — | — |
Indications
No indication recorded.